logo

For the Inventor, By the Inventor

New York, NY, United States of America

Jeffrey N Barton

This inventor holds 15 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Compounds. Top assignees: Usv Pharmaceutical Corporation, Rorer Pharmaceutical Corporation, Aventis Pharma Deutschland, Gmbh. Active years: 1982-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey N Barton. Retrieved from https://idiyas.com/inventor/jeffrey-n-barton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 133(Granted Patents)


Location History:

  • Yonkers, NY (US) (1982)
  • New York, NY (US) (1985 - 1988)
  • Philaddelphia, PA (US) (1996)
  • Philadelphia, PA (US) (1989 - 2003)

Company Filing History:

goldMedal6 out of 128 
 
Usv Pharmaceutical Corporation
 patents
silverMedal5 out of 109 
 
Rorer Pharmaceutical Corporation
 patents
bronzeMedal2 out of 330 
 
Aventis Pharma Deutschland, Gmbh
 patents
4. 2 out of 111 
 
Rhone-Poulenc Rorer Pharmaceuticals Inc.
 patents

Years Active: 1982-2003

Loading Chart...
Loading Chart...
Areas of Expertise:
Sulfonic Acid
Aromatic Oligomers
Benzothiopyranyl Derivatives
Aryl-Substituted Compounds
Antihypertensive Derivatives
Cycloalkyl Compounds
Therapeutic Dipeptides
Pyrrolidines
HMG-CoA Reductase Inhibitors
Azaheterocyclylamide
Carboxyalkyl Dipeptides
Diastereoisomers
15 patents (USPTO):Explore Patents
1. 6602864 - Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds (2003-08-05),
2. 6281227 - Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds (2001-08-28),
3. 5571506 - Aromatic oligomeric compounds useful as mimics of bioactive (1996-11-05),
4. 5114964 - Aryl-substituted benzocycloalkyl-derived anti-atherosclerotic agents (1992-05-19),
5. 4946860 - Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors (1990-08-07),
6. 4843081 - Aryl and heteroaryl substituted cycloalkyl compounds (1989-06-27),
7. 4795757 - Bisarylamines (1989-01-03),
8. 4749698 - Antihypertensive derivatives (1988-06-07),
9. 4746676 - Carboxyalkyl dipeptide compounds (1988-05-24),
10. 4701461 - Substituted cyclic amines (1987-10-20),
11. 4632929 - Method of hypertensive treatment using phenyl-alkylene-2-pyridyl (1986-12-30),
12. 4569941 - Method of using phenyl-alkylene-2-pyridyl derivatives to increase (1986-02-11),
13. 4542234 - Process for the separation of (S,S) diastereoisomers (1985-09-17),
14. 4500713 - Therapeutic dipeptides (1985-02-19),
15. 4342692 - Pyrrolidines (1982-08-03),

Title: Inventor Profile: Jeffrey N. Barton

Introduction

Jeffrey N. Barton is a distinguished inventor based in New York, NY, known for his significant contributions to the pharmaceutical industry. With 15 patented inventions, Barton has made remarkable strides in the field of pharmacology, particularly in developing compounds aimed at treating various medical disorders.

Latest Patents

Barton’s latest inventions revolve around sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds. These innovative compounds, known as formula I, exhibit useful pharmacological activity and are designed to be integrated into pharmaceutical compositions. They serve as inhibitors of Factor Xa activity, providing crucial support in treating patients with physiological conditions that can be ameliorated through such inhibitory action.

Career Highlights

Throughout his career, Jeffrey N. Barton has worked with renowned organizations such as USV Pharmaceutical Corporation and Rorer Pharmaceutical Corporation. His extensive experience in these reputable firms has allowed him to hone his skills in drug discovery and development.

Collaborations

Barton has collaborated with notable colleagues, including John T. Suh and John R. Regan. These cooperative efforts have contributed to the successful development of his patented inventions, further underscoring his role as a valuable asset in the research community.

Conclusion

Jeffrey N. Barton stands out as a prominent figure in the realm of innovation, with a focus on advancing pharmacological treatments. His 15 patents exemplify his dedication and impact on the medical field, positioning him as a key inventor whose work continues to benefit patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…